INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 428m ago
HOUSE PTR28m ago
SEC 13F28m ago
ROBINHOOD CHAIN27m ago
Corporate insider
AM

Abernethy Matt

Chief Financial OfficerCIK 0001724097

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 1
Max Insider Score25
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
AM
Abernethy MattChief Financial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award · 10b5-1 plan
A—
5,020 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    NEUROCRINE BIOSCIENCES INCChief Financial Officer · Sep 15, 2026
9
AM
Abernethy MattChief Financial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding · 10b5-1 plan
F
$423K
2,709 sh
Sep 11, 2026
Sep 15, 2026
traded Sep 11, 2026
+4d
SEC FORM 4

Evidence

25
AM
Abernethy MattChief Financial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$363K
2,311 sh
Sep 14, 2026Sep 15, 2026
traded Sep 14, 2026
+1dSEC FORM 4

Evidence